Listen
Reason for request
Inclusion on the list of medicines approved for hospital in the new indication: “topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IV-B disease”.
-
Clinical Benefit
| Substantial |
The actual benefit of HYCAMTIN is substantial. |
Clinical Added Value
| minor |
HYCAMTIN combined with cisplatin only provides a minor improvement in actual benefit (IAB IV) in terms of efficacy compared to cisplatin in treatment of carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IV-B disease. |
Contact Us
Évaluation des médicaments
